Author details

Mehrdad Payandeh\*, Masoud Sadeghi, Edris Sadeghi and Mehrnoush Aeinfar

\*Address all correspondence to: md.payandeh@yahoo.com

Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

[13] Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC. DNMT3A mutations in acute myeloid leukemia. New England

Role of Genetic Analysis in New Treatments of Acute Myeloid Leukemia

http://dx.doi.org/10.5772/intechopen.76050

153

[14] Martens JHA, Stunnenberg HG. The molecular signature of oncofusionproteins in acute

[15] Yohe S. Molecular genetic markers in acute myeloid leukemia. Journal of Clinical Medi-

[16] Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. The New England

[17] Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from cancer and leukemia group B

[18] Mrozek K, Radmacher MD, Bloomfield CD, Marcucci G. Molecular signatures in acute

[19] Mitelman F, Johansson B, Mertens F, editors. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer 2010. Available from: http://cgap.nci.nih.gov/Chromo-

myeloid leukemia. Current Opinion in Hematology. 2009;16:64-69

Journal of Medicine. 2010;363:2424-2433

Journal of Medicine. 2015;373:1136-1152

(CALGB 8461). Blood. 2002;100:4325-4336

cine. 2015;4:460-478

somes/Mitelman

myeloid leukemia. FEBS Letters. 2010;584:2662-2669
